![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NT5DC1 |
Gene summary for NT5DC1 |
![]() |
Gene information | Species | Human | Gene symbol | NT5DC1 | Gene ID | 221294 |
Gene name | 5'-nucleotidase domain containing 1 | |
Gene Alias | C6orf200 | |
Cytomap | 6q22.1 | |
Gene Type | protein-coding | GO ID | GO:0006793 | UniProtAcc | Q5TFE4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
221294 | NT5DC1 | LZE4T | Human | Esophagus | ESCC | 6.95e-18 | 3.20e-01 | 0.0811 |
221294 | NT5DC1 | LZE7T | Human | Esophagus | ESCC | 1.49e-06 | 1.38e-01 | 0.0667 |
221294 | NT5DC1 | LZE8T | Human | Esophagus | ESCC | 9.23e-14 | 2.70e-01 | 0.067 |
221294 | NT5DC1 | LZE20T | Human | Esophagus | ESCC | 1.14e-04 | 1.26e-01 | 0.0662 |
221294 | NT5DC1 | LZE24T | Human | Esophagus | ESCC | 8.69e-15 | 4.47e-01 | 0.0596 |
221294 | NT5DC1 | P1T-E | Human | Esophagus | ESCC | 3.47e-05 | 3.02e-01 | 0.0875 |
221294 | NT5DC1 | P2T-E | Human | Esophagus | ESCC | 9.64e-55 | 9.35e-01 | 0.1177 |
221294 | NT5DC1 | P4T-E | Human | Esophagus | ESCC | 7.22e-25 | 6.27e-01 | 0.1323 |
221294 | NT5DC1 | P5T-E | Human | Esophagus | ESCC | 7.53e-14 | 2.77e-01 | 0.1327 |
221294 | NT5DC1 | P8T-E | Human | Esophagus | ESCC | 6.72e-13 | 1.52e-01 | 0.0889 |
221294 | NT5DC1 | P9T-E | Human | Esophagus | ESCC | 6.61e-17 | 1.01e-01 | 0.1131 |
221294 | NT5DC1 | P10T-E | Human | Esophagus | ESCC | 3.23e-27 | 4.36e-01 | 0.116 |
221294 | NT5DC1 | P11T-E | Human | Esophagus | ESCC | 1.54e-12 | 2.17e-01 | 0.1426 |
221294 | NT5DC1 | P12T-E | Human | Esophagus | ESCC | 1.23e-46 | 9.18e-01 | 0.1122 |
221294 | NT5DC1 | P15T-E | Human | Esophagus | ESCC | 1.24e-38 | 9.48e-01 | 0.1149 |
221294 | NT5DC1 | P16T-E | Human | Esophagus | ESCC | 1.40e-33 | 6.13e-01 | 0.1153 |
221294 | NT5DC1 | P17T-E | Human | Esophagus | ESCC | 2.66e-10 | 4.27e-01 | 0.1278 |
221294 | NT5DC1 | P20T-E | Human | Esophagus | ESCC | 6.26e-24 | 3.73e-01 | 0.1124 |
221294 | NT5DC1 | P21T-E | Human | Esophagus | ESCC | 3.75e-51 | 8.91e-01 | 0.1617 |
221294 | NT5DC1 | P22T-E | Human | Esophagus | ESCC | 6.57e-20 | 2.75e-01 | 0.1236 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:00163115 | Liver | NAFLD | dephosphorylation | 69/1882 | 417/18723 | 2.27e-05 | 6.23e-04 | 69 |
GO:001631111 | Liver | Cirrhotic | dephosphorylation | 130/4634 | 417/18723 | 1.58e-03 | 1.03e-02 | 130 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:00163116 | Lung | IAC | dephosphorylation | 75/2061 | 417/18723 | 1.21e-05 | 3.64e-04 | 75 |
GO:001631112 | Lung | AIS | dephosphorylation | 69/1849 | 417/18723 | 1.27e-05 | 4.78e-04 | 69 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:00163118 | Prostate | BPH | dephosphorylation | 98/3107 | 417/18723 | 1.53e-04 | 1.35e-03 | 98 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NT5DC1 | SNV | Missense_Mutation | c.709N>A | p.Asp237Asn | p.D237N | Q5TFE4 | protein_coding | deleterious(0.03) | benign(0.314) | TCGA-BH-A0BA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
NT5DC1 | insertion | In_Frame_Ins | novel | c.136_137insAGTTGTGCAAACACAGAACTGAGT | p.Gly46delinsGluLeuCysLysHisArgThrGluTrp | p.G46delinsELCKHRTEW | Q5TFE4 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
NT5DC1 | SNV | Missense_Mutation | novel | c.1161N>T | p.Glu387Asp | p.E387D | Q5TFE4 | protein_coding | tolerated(0.26) | benign(0.098) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NT5DC1 | SNV | Missense_Mutation | c.517N>C | p.Ser173Pro | p.S173P | Q5TFE4 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NT5DC1 | SNV | Missense_Mutation | novel | c.935N>A | p.Gly312Asp | p.G312D | Q5TFE4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2E-A9G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | CR |
NT5DC1 | SNV | Missense_Mutation | rs371466347 | c.1286N>A | p.Ser429Tyr | p.S429Y | Q5TFE4 | protein_coding | deleterious(0) | possibly_damaging(0.89) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5DC1 | SNV | Missense_Mutation | novel | c.1193C>A | p.Ser398Tyr | p.S398Y | Q5TFE4 | protein_coding | tolerated(0.86) | benign(0.439) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5DC1 | SNV | Missense_Mutation | novel | c.169N>A | p.Glu57Lys | p.E57K | Q5TFE4 | protein_coding | tolerated(0.19) | possibly_damaging(0.553) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
NT5DC1 | SNV | Missense_Mutation | novel | c.752A>C | p.Lys251Thr | p.K251T | Q5TFE4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NT5DC1 | SNV | Missense_Mutation | novel | c.1325C>A | p.Pro442His | p.P442H | Q5TFE4 | protein_coding | deleterious(0.03) | possibly_damaging(0.708) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |